eMagin Corporation (AMEX: EMAN) shares are 286.85% up in the year-to-date (YTD) period and have moved -2.92% or -$0.04 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +850.00% lower. Comparatively, the stock is -30.00% down YTD and 139.99% over the trailing 3-month period. If we look at the shorter duration, its week performance is 3.10% and 22.02% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
On December 16, 2014, H.C. Wainwright recommended the EMAN stock is a Buy, while earlier, Rodman & Renshaw had Resumed the stock as a Buy on June 23, 2017. 1 analysts offering the recommendations for the stock have a consensus rating of 2.00 to suggest that the EMAN stock is a “Moderate Buy. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $1.33 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $2.00. The forecasts give the eMagin Corporation stock a price target range of $2.00 on the higher side while at least one analyst think the stock could plunge to a low of $2.00. The two limits represent an upside potential of 33.5% or 33.5%.
Analysts estimate the earnings to decrease -400.00% in the current quarter to -$0.02, up from the -$0.05 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$0.13, up 10.00% from -$0.09 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.03 and -$0.03. Wall Street estimates earnings per share to be at an average of -$0.1 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 2 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 56,578 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Koch Mark A, a CFO at the company, bought 25,000 shares worth $6000.0 at $0.24 per share on Mar 12. The Director had earlier bought another 31,578 EMAN shares valued at $6000.0 on Mar 16. The shares were bought at $0.19 per share.
Inovio Pharmaceuticals Inc. (NASDAQ:INO), on the other hand, is trading around $11.99 with a market cap of $1.97B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $19.00 and spell out a more modest performance – a 36.89% return. Some analysts are even forecasting -$1.47 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Inovio Pharmaceuticals Inc. (INO) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
INO’s operating expenses over the recent quarter were at -$33.18 million. This represented a 12527.34% of the company’s total revenues which amounted $0.27 million. With this in place, we can see that the company’s diluted EPS declined -$0.83 on the year-over-year period, shrinking to -$0.30 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $443.19 million from $338.92 million over the previous quarter. Short term investments amounted to $156.23 million while total current assets were at $382.06 million. The cash flow from operating activities totaled -$52.6 million, significantly higher than the -$56.38 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$52.78 million.
Insiders have transacted a total of 42 times at Inovio Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 22 times and accounting for 557,015 shares. Insider sales totaled 379,248 shares over the same period, with these deals completed in 20 transactions. Looking at these numbers, we realize that net purchases over that period are 2.0 shares. Insiders now hold a total of 4.51M shares after the latest sales, with 7.80% net shares purchased.
Insiders own 1.40% of the company shares, while shares held by institutions stand at 34.10% with a share float percentage of 164.19M. Investors are also buoyed by the number of investors in a company, with Inovio Pharmaceuticals Inc. having a total of 163 institutions that hold shares in the company.